#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14332	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2066	688.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1429	1429	C	862	C,A,G	809,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26496	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3770	701.3	0	.	n	.	0	T695C	SNP	695	695	T	1188	1188	C	813	C	768	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26496	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3770	701.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1830	1830	A	861	A	803	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26496	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3770	701.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2464	2464	C	820	C,T	764,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26496	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3770	701.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2538	2538	A	841	A	796	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26496	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3770	701.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3090	3090	C	806	C,T	756,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1906	folP	852	852	100.0	folP.l15.c30.ctg.1	1545	122.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1026	1028	AGC	202;203;203	A;G;C	185;186;187	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4890	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3447	141.6	1	SNP	p	S91F	0	.	.	271	273	TCC	605	607	TCC	176;177;176	T;C;C	159;161;162	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4890	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3447	141.6	1	SNP	p	D95N	0	.	.	283	285	GAC	617	619	GAC	179;181;181	G;A;C	165;166;168	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4890	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3447	141.6	1	SNP	p	D95G	0	.	.	283	285	GAC	617	619	GAC	179;181;181	G;A;C	165;166;168	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1398	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1279	108.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	413	415	ACC	165;162;161	A;C;C	148;150;149	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1398	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1279	108.9	0	.	p	.	0	R44H	NONSYN	130	132	CGC	428	430	CAC	156;158;160	C;A;C	144;142;147	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1398	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1279	108.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	611	613	CAC	212;212;213	C;A;C	194;191;195	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1398	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1279	108.9	1	SNP	p	G45D	0	.	.	133	135	GGC	431	433	GGC	161;162;164	G;G;C	147;148;150	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	854	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	919	92.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4926	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3019	162.7	1	SNP	p	D86N	0	.	.	256	258	GAC	569	571	GAC	194;191;192	G;A;C	186;182;184	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4926	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3019	162.7	1	SNP	p	S87I	0	.	.	259	261	AGT	572	574	AGT	195;195;196	A;G;T	186;187;185	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4926	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3019	162.7	1	SNP	p	S87W	0	.	.	259	261	AGT	572	574	AGT	195;195;196	A;G;T	186;187;185	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4926	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3019	162.7	1	SNP	p	S87R	0	.	.	259	261	AGT	572	574	AGT	195;195;196	A;G;T	186;187;185	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4926	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3019	162.7	1	SNP	p	S88P	0	.	.	262	264	TCC	575	577	TCC	197;199;199	T;C;C	186;187;188	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3938	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2522	155.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1425	1427	GGC	183;186;185	G;G;C	171;172;173	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1268	1270	GCA	243;242;242	G;C;A	225;225;223	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1271	1273	ATC	242;241;241	A;T;C,T	223;224;224,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1283	1285	GTG	243;238;236	G;T;G	225;222;221	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1283	1285	GTG	243;238;236	G;T;G	225;222;221	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1787	1789	ACC	173;172;169	A;C;C	159;161;159	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1841	1843	GCG	171;171;168	G;C;G	152;138;142	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1841	1843	GCG	171;171;168	G;C;G	152;138;142	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1964	1966	GGC	144;141;140	G;G;C	134;131;130	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1973	1975	GGC	130;129;131	G;G;C	118;114;115	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3874	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2434	158.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1991	1993	CCG	115;120;121	C,G;C,T;G	87,2;89,1;91	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5352	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3187	167.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2154	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1896	113.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	644	644	C	152	C	138	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	304	porB1a	984	297	91.36	porB1a.l15.c30.ctg.1	1287	22.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1015	1017	AAT	26;26;25	A;A;T	26;26;25	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	304	porB1a	984	297	91.36	porB1a.l15.c30.ctg.1	1287	22.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1018	1020	AAT	25;24;24	A;A;T	25;24;24	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	304	porB1a	984	297	91.36	porB1a.l15.c30.ctg.1	1287	22.1	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1030	1032	GTT	25;24;24	G;T;T	25;24;23	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	304	porB1a	984	297	91.36	porB1a.l15.c30.ctg.1	1287	22.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1042	1044	GCA	24;24;24	G;C;A	24;24;24	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	304	porB1a	984	297	91.36	porB1a.l15.c30.ctg.1	1287	22.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1065	1067	GTA	25;24;24	G;T;A	25;24;24	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	304	porB1a	984	297	91.36	porB1a.l15.c30.ctg.1	1287	22.1	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1077	1077	G	28	G	27	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	438	440	GGA	223;225;228	G;G;A	209;210;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	699	701	CTT	216;220;219	C;T;T	206;209;210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	723	725	GGA	215;215;214	G;G;A	201;200;193	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	807	809	GGT	240;240;239	G;G;T	224;225;217	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	861	863	AGC	196;193;192	A;G;C	186;184;184	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	G203V	NONSYN	607	609	GGC	903	905	GTC	156;153;151	G;T;C	147;144;141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	927	927	T	148	T	141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	1	SNP	p	G120K	0	.	.	358	360	GGT	654	656	GGT	197;197;201	G;G;T	185;189;186	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	1	SNP	p	A121D	0	.	.	361	363	GCC	657	659	GCC	203;200;201	G;C;C	191;190;194	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2596	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1493	172.4	1	SNP	p	A121N	0	.	.	361	363	GCC	657	659	GCC	203;200;201	G;C;C	191;190;194	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10254	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4741	215.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1934	1936	AAT	217;218;216	A;A;T	203;205;201	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1054	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	967	107.9	1	SNP	p	V57M	1	.	.	169	171	ATG	421	423	ATG	222;223;222	A;T;G	208;211;209	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
